Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results

Hansa Biopharma AB Sweden

Hansa secures directed cash share issue of approximately 232 MSEK/US $24.3M and restructures NovaQuest debt.As compared to prior year Q2 IDEFIRIX product sales increased 76%.and will also be made available online after the call.

To participate in the telephone conference, please use the dial-in details provided below:
Participant Dial In (Toll Free): 1-833-821-3542
Participant International Dial In: 1-412-652-1248
*Please ask to be joined into the Hansa Biopharma call

Join the webcast here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=hUSedAeI

Contacts for more information:
Evan Ballantyne, Chief Financial Officer
[e-mail]

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-reports-second-quarter-and-interim-january-june-2025-financial-results,c4208006

The following files are available for download:

https://mb.cision.com/Main/1219/4208006/3583230.pdf

20250717_HNSA_Q22025_QuarterlyReport_ENG

 

View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-reports-second-quarter-and-interim-january-june-2025-financial-results-302507683.html